Physician profile
Mohammad Umar Ahmed
NPI 1912528225
$4,043.62
in general payments reported to CMS, 2019-2025
12 companies · $2,072 in 2025
The $2,072 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $271 · 2024: $1,700 · 2025: $2,072.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,770 · Travel and Lodging: $1,760 · Education: $514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,769.95 |
| Travel and Lodging | $1,759.97 |
| Education | $513.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $2,830.25 | 2024-2025 | Barostim Neo System |
| Abbott Laboratories | $513.70 | 2024-2025 | Ensite |
| Abiomed | $146.31 | 2023 | Impella |
| United Therapeutics Corporation | $124.99 | 2023 | Remodulin |
| Bard Peripheral Vascular, INC. | $114.44 | 2024 | Rotarexs 6 F X 135 Cm |
| E.R. Squibb & Sons, L.L.C. | $88.03 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $81.06 | 2025 | Opsumit, Uptravi |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $50.29 | 2024-2025 | Lifevest |
| Baxter Healthcare | $30.01 | 2025 | Hillrom - Cardiac Ambulatory Monitor |
| Astrazeneca Pharmaceuticals LP | $25.82 | 2025 | |
| Bridgebio Pharma, INC. | $24.39 | 2025 | Attruby |
| Janssen Pharmaceuticals, INC | $14.33 | 2024 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.